2018 Press Releases

Webcast ImageWebcast
MyoKardia AHA Call (Replay)
November 12, 2018 at 8:00 a.m. ET
MyoKardia AHA Call
Monday, November 12, 2018 8:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
MyoKardia Inc at the Credit Suisse Healthcare Conference (Replay)
November 14, 2018 at 9:10 a.m. MT
MyoKardia Inc at the Credit Suisse Healthcare Conference
Wednesday, November 14, 2018 9:10 a.m. MT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
11/12/18MyoKardia Presents Preclinical Evidence of Mavacamten’s Novel Effect on Diastolic Compliance at the 2018 American Heart Association Scientific Sessions
Improved Left Ventricular Compliance Demonstrated in Genetic Pig Model of Non-Obstructed Hypertrophic Cardiomyopathy Results Add to Growing Body of Evidence of Mavacamten’s Dual Activity in Increasing Compliance and Reducing Hypercontractility MyoKardia to Conduct Conference Call at 8:00 a.m. ET Today to Discuss Clinical, Preclinical and Registry Data Presented at AHA 2018 SOUTH SAN FRANCISCO, Calif., Nov. 12, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage bioph... 
11/07/18MyoKardia Reports Third Quarter 2018 Financial Results
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today reported financial results for the quarter ended September 30, 2018.  “MyoKardia continues to make encouraging progress toward our mission of changing the world for patients with serious cardiovascular disease. Within just the past few months, we have initiated the MAVA-LTE ... 
11/07/18MyoKardia to Present at the Credit Suisse 27th Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced today announced that Jake Bauer, Chief Business Officer, will provide a corporate update at the Credit Suisse 27th Annual Healthcare Conference on Wednesday, November 14, 2018, at 9:10 a.m. MT (11:10 a.m. ET) in Scottsdale, Arizona. A webcast of the presentation wi... 
11/05/18MyoKardia to Present Clinical Evidence of Mavacamten’s Effect on Diastolic Function at 2018 American Heart Association Scientific Sessions
Diastolic Relaxation Typically Impaired in HCM Patients; Data Indicate Mavacamten May Improve Ability of the Left Ventricle to Relax and Fill Additional Clinical Evidence of Mavacamten’s Effect on Diastolic Function Expected in 2H 2019 from MyoKardia’s MAVERICK-HCM Phase 2 Trial in Patients with Non-Obstructive HCM SOUTH SAN FRANCISCO, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the t... 
11/05/18MyoKardia Announces Twelve Abstracts Accepted for Presentation During the 2018 American Heart Association Scientific Sessions
Presentations Include Data from Ongoing Clinical Trials and Preclinical Studies of Mavacamten and HCM Population Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe) MyoKardia Management to Host a Conference Call on November 12 at 8:00 a.m. ET to Review Data SOUTH SAN FRANCISCO, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) --  MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, to... 
10/30/18MyoKardia Shares Data from Ongoing Clinical Programs and Details Three New Research Programs at 2018 R&D Day
Interim PIONEER-OLE Data for Mavacamten Demonstrate Reductions in LVOT Obstruction; Ejection Fraction Maintained above Normal Range First-in-Human Data for MYK-491 in Healthy Volunteers Presented; Phase 2a Multiple-ascending Dose Trial Initiated Introduced MYK-224, ACT-1 and LUS-1: Each with Distinct Mechanisms Targeting Diseases of Cardiac Contractility Detailed Ongoing Efforts to Improve HCM Disease Awareness SOUTH SAN FRANCISCO, Calif., Oct. 30, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc.,... 
10/25/18MyoKardia Announces Initiative to Create Hypertrophic Cardiomyopathy Patient Community in Collaboration with 23andMe
First-of-its-kind Digital Platform for HCM Patients Intended to Provide a Powerful Patient Resource to Improve Disease Understanding and Deepen Patient Engagement and Advocacy SOUTH SAN FRANCISCO, Calif., Oct. 25, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc., (Nasdaq: MYOK), a clinical stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced that it has entered into a collaboration with 23andMe to advance research for patients w... 
10/24/18MyoKardia Doses First Patient in MAVA Long-Term Extension Study of Mavacamten for Hypertrophic Cardiomyopathy
Key Remaining Study in Registration Program for oHCM Enables Assessment of Mavacamten’s Potential for Disease Modification SOUTH SAN FRANCISCO, Calif., Oct. 24, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced that patient dosing has begun in the MAVA Long-Term Extension (MAVA-LTE) clinical trial. The MAVA-LTE study will assess long-term safety of mav... 
10/22/18MyoKardia to Host R&D Day on October 30, 2018
SOUTH SAN FRANCISCO, Calif., Oct. 22, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced that it will host a Research and Development (R&D) Day for analysts and investors on Tuesday, October 30, 2018 beginning at 8:00 a.m. ET (5:00 a.m. PT) in New York City. In addition to presentations by MyoKardia’s management team, which will review the company’... 
09/24/18MyoKardia to Present at the 2018 Cantor Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced that Tassos Gianakakos, Chief Executive Officer, will present at the 2018 Cantor Global Healthcare Conference on Monday, October 1, 2018, at 10:05 a.m. ET in New York, NY.  A webcast of the presentation will be available by visiting the Investors section of MyoKar... 
09/20/18MyoKardia Launches Inaugural MyoSeeds™ Research Grants Program to Advance Independent Research in Heart Disease
Program Intended to Accelerate Innovation in the Biology and Underlying Mechanisms of Cardiomyopathies to help Enable Treatment BreakthroughsUp to Four, $250,000 Grants Available in Inaugural Round SOUTH SAN FRANCISCO, September 20, 2018 – MyoKardia, a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced the launch of the MyoSeeds™ Research Grants Program, a new initiative to support original, independent research in... 
08/29/18MyoKardia to Present at Two Upcoming Investor Conferences in September
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced that senior company management will be participating in the following upcoming investor conferences: 2018 Wells Fargo Healthcare Conference in Boston, MA on Wednesday, September 5, 2018 at 8:30 a.m. ET   Morgan Stanley 16th Annual Global Healthcare Conferen... 
08/23/18New Insights on Disease Burden for Hypertrophic Cardiomyopathy Patients Published in Circulation
HCM Patients at Greater Risks of Atrial Fibrillation, Heart Failure and Increased Mortality Younger Age of Diagnosis and Genetic Status Associated with Higher Rates of Long-term Complications and Early Death SOUTH SAN FRANCISCO, Calif., Aug. 23, 2018 (GLOBE NEWSWIRE) -- The Sarcomeric Human Cardiomyopathy Registry (SH... 
08/08/18MyoKardia Reports Second Quarter 2018 Financial Results
Company to Host Conference Call and Webcast Today at 4:30 p.m. ET (1:30 p.m. PT) SOUTH SAN FRANCISCO, Calif., Aug. 08, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today reported financial results for the quarter ended June 30, 2018.  “This quarter saw MyoKardia initiate three new clinical studies, including the advancement of our lead investigational compound,... 
08/07/18MyoKardia to Present at the 2018 Wedbush Pacgrow Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that Tassos Gianakakos, Chief Executive Officer,  will present at the 2018 Wedbush Pacgrow Healthcare Conference on Tuesday, August 14, 2018, at 10:55 a.m. ET in New York, NY.  A webcast of the presentation will be available by visiting the Invest... 
08/01/18MyoKardia to Report Second Quarter 2018 Financial Results on Wednesday, August 8, 2018
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that it will report second quarter 2018 financial and operating results on Wednesday, August 8, 2018. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 4:30 p.m. ET (1:30 p.m. P... 
06/26/18MyoKardia Doses First Patient in Pivotal Phase 3 EXPLORER-HCM Trial of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy
Topline Data Anticipated in Second Half 2020 SOUTH SAN FRANCISCO, Calif., June 26, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that the first patient has been dosed in the company’s Phase 3 EXPLORER-HCM clinical trial.  The pivotal study is intended to evaluate the efficacy and safety of mavacamten for the treatment of symptoma... 
05/22/18MyoKardia Announces Pricing of Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., May 22, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the pricing of an underwritten public offering of 3,750,000 shares of its common stock at a public offering price of $49.00 per share, before underwriting discounts. In addition, the underwriters have a 30-day option to purchase an additional 562,50... 
05/21/18MyoKardia Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., May 21, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that it has commenced a proposed underwritten public offering of 3,750,000 shares of its common stock. All shares of common stock will be offered by MyoKardia. In addition, MyoKardia expects to grant the underwriters a 30-day option to purchase an a... 
05/21/18MyoKardia Announces Design of Phase 3 EXPLORER-HCM Study Evaluating Mavacamten in Symptomatic, Obstructive Hypertrophic Cardiomyopathy
Single Pivotal to Support Registration; Target Enrollment of 220 Patients; Primary Endpoint of Clinical Response Using Peak VO2 and NYHA Classification Improvements Expected to Initiate in Second Quarter 2018; Topline Data Anticipated in Second Half 2020 Management to Host Conference Call Today at 8:30 a.m. ET/5:30 a.m. PT SOUTH SAN FRANCISCO, Calif., May 21, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine ... 
05/10/18MyoKardia to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
SOUTH SAN FRANCISCO, Calif., May 10, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that Tassos Gianakakos, Chief Executive Officer,  will present at the Bank of America Merrill Lynch Health Care Conference on Tuesday, May 15, 2018, at 11:20 a.m. PT (2:20 p.m. ET) in Las Vegas, NV.   A webcast of the presentation will be availab... 
05/10/18MyoKardia Doses First Patient in PIONEER Open-Label Extension Study of Mavacamten for Symptomatic, Obstructive Hypertrophic Cardiomyopathy
SOUTH SAN FRANCISCO, Calif., May 10, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the start of the PIONEER open-label extension (OLE) study of its investigational drug, mavacamten.  MyoKardia recently completed the Phase 2 PIONEER-HCM clinical study of mavacamten in patients with symptomatic, obstructive hypertrophic cardiomyopat... 
05/08/18MyoKardia Reports First Quarter 2018 Financial Results
Company to Host Conference Call and Webcast Today at 4:30 p.m. ET (1:30 p.m. PT) SOUTH SAN FRANCISCO, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today reported financial results for the quarter ended March 31, 2018.   “This is a busy and productive time for MyoKardia. We are on track to initiate a total of six clinical tria... 
05/03/18MyoKardia to Report First Quarter 2018 Financial Results on Tuesday, May 8, 2018
SOUTH SAN FRANCISCO, Calif., May 03, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that it will report first quarter 2018 financial and operating results after the U.S. financial markets close on Tuesday, May 8, 2018. Management will host a conference call and live audio webcast to discuss these results and provide a business upda... 
04/04/18MyoKardia Announces Appointment of Taylor C. Harris as Chief Financial Officer
SOUTH SAN FRANCISCO, Calif., April 04, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the appointment of Taylor C. Harris as Chief Financial Officer.  Mr. Harris brings more than 20 years of finance and life science industry experience to MyoKardia and will lead the finance, accounting, information technology, facilities, corporate... 
04/02/18MyoKardia Begins Dosing in Phase 2 MAVERICK-HCM Clinical Trial of Mavacamten in Symptomatic Non-obstructive Hypertrophic Cardiomyopathy Patients
Topline Data Anticipated in Second Half of 2019 SOUTH SAN FRANCISCO, Calif., April 02, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that the first patient has been dosed in the company’s Phase 2 MAVERICK-HCM clinical trial.  MAVERICK-HCM is the first clinical trial of mavacamten in non-obstructive HCM, expanding its potential us... 
03/08/18MyoKardia Reports Fourth Quarter and Full Year 2017 Financial Results
Announced Achievement of Primary Endpoint and Additional Key Data from Low-Dose Mavacamten Cohort of PIONEER-HCM Phase 2 Study in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Company to Host Conference Call and Webcast Today at 4:30 p.m. ET (1:30 p.m. PT) SOUTH SAN FRANCISCO, Calif., March 08, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular d... 
03/08/18MyoKardia Announces Positive Results from Low-Dose Cohort of Phase 2 PIONEER-HCM Study of Mavacamten in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients
Met Primary Endpoint and Key Secondary Endpoints with Statistical Significance Study Results Inform Phase 3 EXPLORER-HCM Dosing; First Patient Planned for Q2 2018 Conference Call Today at 4:30 p.m. ET (1:30 p.m. PT); Data Presentation at American College of Cardiology on Sunday, March 11, 2018 SOUTH SAN FRANCISCO, Calif., March 08, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatmen... 
03/06/18MyoKardia to Present at the Cowen and Company 38th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that Tassos Gianakakos, Chief Executive Officer,  will present at the Cowen and Company 38th Annual Health Care Conference on Tuesday, March 13, 2018, at 9:20 a.m. ET in Boston, MA.   A webcast of the presentation will be available by visiting ... 
03/01/18MyoKardia to Report Fourth Quarter and Full Year 2017 Financial Results on Thursday, March 8, 2018
SOUTH SAN FRANCISCO, Calif., March 01, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that it will report fourth quarter and full year 2017 financial and operating results after the U.S. financial markets close on Thursday, March 8, 2018. Management will host a conference call and live audio webcast to discuss these results and pro... 
02/14/18MyoKardia to Present at the RBC Capital Markets’ 2018 Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Feb. 14, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that senior management will participate in a fireside chat at the RBC Capital Markets’ 2018 Healthcare Conference on Wednesday, February 21, 2018, at 8:30 a.m. ET in New York, NY.   A webcast of the presentation will be available by visiting the... 
02/14/18MyoKardia Begins Patient Dosing in Phase 1b Clinical Study of MYK-491 in Dilated Cardiomyopathy Patients
Topline Results from First-in-Human Phase 1 Study of MYK-491 in Healthy Volunteers Demonstrated Tolerability and Increased Contractility SOUTH SAN FRANCISCO, Calif., Feb. 14, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that dosing has commenced in a Phase 1b single-ascending dose patient study of its investigational drug candid... 
01/19/18MyoKardia Announces Appointment of Cynthia Ladd as General Counsel
SOUTH SAN FRANCISCO, Calif., Jan. 19, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the expansion of its executive committee with the appointment of Cynthia Ladd as General Counsel. “Cynthia brings substantial experience as a biotech executive and expertise in intellectual property, business development, corporate governance an... 
01/03/18MyoKardia to Present at 36th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that Tassos Gianakakos, Chief Executive Officer, is scheduled to present at the 36th Annual J.P. Morgan Healthcare Conference on Tuesday, January 9th, 2018, at 2:30 p.m. PT (5:30 p.m. ET) in San Francisco. A webcast of the presentation will be a...